--(BUSINESS WIRE)--Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus’ strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology. For more information, please visit Aeolus’ corporate website at www.aeoluspharma.com.
|
Company: |
Aeolus Pharmaceuticals, Inc. | ||
|
Headquarters Address: |
26361 Crown Valley Parkway, Suite 150 | ||
| Mission Viejo, CA 92691 | |||
|
Main Telephone: |
949-481-9820 |
||
|
|
|||
|
Ticker: |
AOLS(OTCBB) | ||
|
Type of Organization: |
Public | ||
|
Industry: |
Biotechnology | ||
|
Key Executives: |
CEO: John McManus |
||
|
CFO: Russell Skibsted |
|||
|
Chairman: David Cavalier |
|||
|
Investor Relations |
|||
|
Contact: |
Russell Skibsted |
||
|
Phone: |
949-481-9825 |
||
|
Email: |